Steve Potts is a dynamic sales-oriented science executive with 20+ years of experience in oncology, including general management and CEO leadership of drug development. He has a demonstrated track record at both early and mid stage small biotechs, as well as experience within Fortune 500 environment. Recognized technical leader in oncology clinical trial execution and enrollment initiatives, the use of artificial intelligence (image analysis) in anatomic pathology for drug development, and the scaling of cancer next gen sequence testing in oncology globally.
He has had three 8x minimum exits to investors., twice building companies from scratch (Flagship – 8x exit to investors, OncoMyx therapeutics) and three times building technology that became major parts of larger companies (Quest Diagnostics Bioinformatics division – now $2B in annual revenue; Aperio – digital pathology now Leica/Danaher and an industry standard; and Ignyta, now Roche rozlytrek.com precision oncology drug).
He has had three 8x minimum exits to investors., twice building companies from scratch (Flagship – 8x exit to investors, OncoMyx therapeutics) and three times building technology that became major parts of larger companies (Quest Diagnostics Bioinformatics division – now $2B in annual revenue; Aperio – digital pathology now Leica/Danaher and an industry standard; and Ignyta, now Roche rozlytrek.com precision oncology drug).
Speaking In
2:00 PM - 4:00 PM
Tuesday, June 6
